Fluorescent Block Copolymers for Self-Reporting Biodegradable Implants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing fluorescent micelles for biomedical applications face issues such as low fluorophore-to-micelle ratios, increased size, cytotoxicity, and premature leakage, which hinder their effectiveness in theranostic and imaging applications, and existing polylactones lack self-reporting capabilities for in vivo monitoring of implant degradation.
Innovation Solution
Development of amphiphilic block copolymers that self-assemble into luminescent or fluorescent micelles with a hydrophobic core and hydrophilic corona, capable of in situ monitoring of implant degradation and theranostic applications without additional imaging agents, using blocks formed from polycarboxylic acids, polyols, and amino acids, which are biodegradable and non-toxic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If fluorescent organic dyes, quantum dots, or gold nanoparticles are conjugated or encapsulated on or within micelles, then fluorescent properties are provided to micelles, but fluorophore-to-micelle ratios are low, micelle size increases, photo-bleaching resistance deteriorates, and cytotoxicity increases
Solution Approach 1:
The patent merges the fluorescent properties directly into the polymer structure by incorporating fluorophores into the polymer backbone or side chains during polymerization, creating intrinsically fluorescent polymers. This eliminates the need for separate conjugation or encapsulation steps, thereby maintaining high fluorophore-to-micelle ratios while reducing micelle size and cytotoxicity.
Solution Approach 2:
The patent uses composite materials by combining fluorophore-containing monomers with polymerizable monomers to create fluorescent block copolymers. These copolymers self-assemble into micelles with fluorescent blocks forming the core or corona, providing intrinsic fluorescence without requiring additional imaging agents, thus avoiding the cytotoxicity and size increase associated with conventional approaches.
2Illumination intensity
If fluorescent organic dyes, quantum dots, or gold nanoparticles are conjugated or encapsulated on or within micelles, then fluorescent properties are provided to micelles, but micelle size increases
Solution Approach 1:
The patent merges fluorescent properties into the polymer structure itself, eliminating the need for separate fluorophore conjugation that would increase micelle size. The fluorescent blocks are integrated into the micelle structure during self-assembly, maintaining compact size while providing fluorescence.
3Illumination intensity
If fluorescent organic dyes, quantum dots, or gold nanoparticles are conjugated or encapsulated on or within micelles, then fluorescent properties are provided to micelles, but fluorophore-to-micelle ratios are low
Solution Approach 1:
The patent merges fluorophores into the polymer backbone or side chains during polymerization, ensuring that every polymer chain contains fluorophores. This results in high fluorophore-to-micelle ratios because the fluorophores are an integral part of the micelle structure rather than being added separately in limited quantities.
4Duration of action of stationary object
If existing polylactones are used for biomedical implants, then biodegradability is provided, but self-reporting capabilities for in vivo monitoring of implant degradation are lacking
Solution Approach 1:
The patent creates multi-functional polylactone block copolymers that simultaneously provide structural support for implants, biodegradability for safe breakdown, and intrinsic fluorescence for real-time monitoring. The fluorescent blocks enable self-reporting of degradation without requiring separate imaging agents, thus gaining monitoring capability while maintaining biodegradability.
5Adaptability or versatility
If conjugation and/or encapsulation of imaging agents by polylactones is performed, then theranostic capabilities are provided, but particle size dramatically increases, cost or complexity increases, and risk of adverse biological reactions increases
Solution Approach 1:
The patent merges therapeutic and diagnostic functions into a single polymer structure by incorporating both drug-loading capability (through hydrophobic blocks) and intrinsic fluorescence (through fluorophore-containing blocks) into the same block copolymer. This eliminates the need for separate conjugation and encapsulation processes, significantly reducing complexity while maintaining theranostic capabilities.
Solution Approach 2:
The patent uses composite materials by creating fluorescent block copolymers with distinct hydrophobic and hydrophilic blocks that self-assemble into micelles capable of drug delivery and imaging. This integrated composite structure provides theranostic functionality without the complex multi-step conjugation and encapsulation processes required by conventional approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amphiphilic block copolymers enable efficient in vivo fluorescence imaging and theranostic drug delivery, providing real-time monitoring of implant degradation and tissue regeneration without animal sacrifice, with improved biocompatibility and reduced cytotoxicity.
Implementation Method 1
a block copolymer described herein can be amphiphilic and can self-assemble into a nanoscale micelle, such as a micelle having a hydrophobic core and a hydrophilic corona
Implementation Method 2
a block copolymer described herein can be luminescent or fluorescent and/or biodegradable, facilitating its use in a variety of biological applications, including imaging applications
Data Source
AI summary
In one aspect, block copolymers are described herein. A block copolymer described herein, in some embodiments, comprises a first block comprising a polymer or oligomer formed from the reaction product of (i) a polycarboxylic acid or a polycarboxylic acid equivalent, (ii) a polyol, and (iii) an amino acid; and a second block comprising a polymer or oligomer that differs from the polymer or oligomer of the first block. In some cases, the polycarboxylic acid or polycarboxylic acid equivalent comprises citric acid, a citrate, or an ester of citric acid. The polyol can comprise an α,ω-n-alkane diol, poly(ethylene glycol), or poly(propylene glycol). In some embodiments, the amino acid forms a pendant group of the polymer or oligomer of the first block and/or forms a luminescent 6-membered ring with the polycarboxylic acid or polycarboxylic acid equivalent. The second block of a block copolymer described herein, in some embodiments, comprises a polylactone.